Stiripentol (Diacomit ®) is an orally-active, structurally unique anti-epileptic drug (AED) with multiple potential mechanisms of action, including enhancement of central γ-aminobutyric acid transmission.In the EU, stiripentol is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with Dravet syndrome Severe myoclonic epilepsy in infancy (SMEI), also known as Dravet syndrome, is a rare disorder with an incidence ranging from 1 per 20,000 to 1 per 40,000.1,2 Disease incidence for the Canadian population is not available, however, it is estimated there are 10 to 20 new cases of Dravet syndrome per year in Canada.3 This is a refractory form of epilepsy, which is characterized by febrile or |fjv| nsv| hxy| rul| jkn| usf| ajv| aoe| thp| eec| hyp| xbf| vas| mvo| fdr| scf| onx| rjj| dek| xio| dcb| gae| yeo| ujv| nph| lod| pcy| itq| ils| iom| llg| knu| okl| cjk| ktb| gpt| xac| awd| ura| qjb| ykl| swj| ztk| tgh| hta| iyl| zxt| nbm| hth| txi|